<?xml version="1.0"?>
<doi_batch xmlns="http://www.crossref.org/schema/4.4.2" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:jats="http://www.ncbi.nlm.nih.gov/JATS1" version="4.4.2" xsi:schemaLocation="http://www.crossref.org/schema/4.4.2 http://www.crossref.org/schema/deposit/crossref4.4.2.xsd">
  <head>
    <doi_batch_id>2026-Zeeshan-1</doi_batch_id>
    <timestamp>20240803000000</timestamp>
    <depositor>
      <depositor_name>iarcin:iarcin</depositor_name>
      <email_address>m.arslansohail@gmail.com</email_address>
    </depositor>
    <registrant>IARCON INTERNATIONAL LLP</registrant>
  </head>
  <body>
    <journal>
      <journal_metadata>
        <full_title>Scientific Research Journal of Pharmacy</full_title>
        <abbrev_title>Sci. Res. J. Pharm.</abbrev_title>
        <issn media_type="electronic">2788-9564</issn>
        <doi_data>
          <doi>10.47310/srjp</doi>
          <resource>https://www.iarconsortium.org/srjp/</resource>
        </doi_data>
      </journal_metadata>
      <journal_issue>
        <publication_date media_type="print">
          <month>08</month>
          <day>03</day>
          <year>2024</year>
        </publication_date>
        <publication_date media_type="online">
          <month>08</month>
          <day>03</day>
          <year>2024</year>
        </publication_date>
        <journal_volume>
          <volume>4</volume>
        </journal_volume>
        <issue>1</issue>
        <doi_data>
          <doi>10.47310/srjp.2024.v04i01</doi>
          <resource>https://www.iarconsortium.org/srjp/archives/57/242/</resource>
        </doi_data>
      </journal_issue>
      <journal_article publication_type="full_text">
        <titles>
          <title>Modification of Amoxicillin antibacterial to promising anticancer azomethine derivatives: Synthesis and in vitro studies</title>
          <original_language_title>Modification of Amoxicillin antibacterial to promising anticancer azomethine derivatives: Synthesis and in vitro studies</original_language_title>
        </titles>
        <contributors>
          <person_name sequence="first" contributor_role="author">
            <given_name>Zuhoor</given_name>
            <surname>Abdl Latef Thame</surname>
          </person_name>
          <person_name sequence="additional" contributor_role="author">
            <given_name>Roaa</given_name>
            <surname>Jawad Jaber</surname>
          </person_name>
        </contributors>
        <jats:abstract xml:lang="en">
          <jats:p>The present study provides an original way for synthesizing imines (A and B) by reacting amoxicillin with 2,4-dihydroxybenzaldehyde and 4-methylbenzaldehyde. The derivatives (A and B) were analyzed using FT-IR Spectroscopy. Using the zone inhibition method, the in vitro evaluation of synthesized derivatives (A and B) was conducted against several bacteria, including Streptococcus pneumonia and E. coli. The results indicated that specific derivatives possess enhanced antibacterial capabilities compared to the effectiveness of regular medication. The derivative A was assessed for its anticancer activity against prostate cancer PC3 cells using the MTT assay, which yielded a favorable outcome within 48 hours.</jats:p>
        </jats:abstract>
        <publication_date media_type="online">
          <month>08</month>
          <day>03</day>
          <year>2024</year>
        </publication_date>
        <publication_date media_type="print">
          <month>08</month>
          <day>03</day>
          <year>2024</year>
        </publication_date>
        <pages>
          <first_page>1</first_page>
          <last_page>5</last_page>
        </pages>
        <doi_data>
          <doi>10.47310/srjp.2024.v04i01.003</doi>
          <resource>https://www.iarconsortium.org/srjp/57/242/modification-of-amoxicillin-antibacterial-to-promising-anticancer-azomethine-derivatives-synthesis-and-in-vitro-studies-4533/</resource>
        </doi_data>
      </journal_article>
    </journal>
  </body>
</doi_batch>
